May 29, 2013 - PTCL - Diagnosis & Treatment Update
- PTCL and PTCL subtypes
- Treatment options for patients with newly diagnosed, refractory or relapsed PTCL
- The role of clinical trials as treatment options for patients with PTCL
- Patient-provider communications about treatment options, including clinical trials
- Patient-provider communications about side effects management
Julie M. Vose, MD, MBA
Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology/Hematology
Department of Internal Medicine
University of Nebraska Medical Center
Questions Asked by the PTCL Community
- Are there any blood tests which might be an early detector of recurrence?
- What are the standards of initial medical evaluation and then diagnosis, if there aren't any enlarged nodes and a biopsy can't be done?
- Can a diagnosis of PTCL linger on at a treatable level without significant increase in severity?
- Are there any topical treatments or other medications that you can suggest to help relieve itching?
- Can you please talk about the status of denileukin diftitox (Ontak®) as a targeted therapy?
Is this common to have both an autologous transplant and an allogeneic transplant to treat angioimmunoblastic T-cell lymphoma?
- What is the success rate of an allogeneic transplant?
- If the disease comes back, is getting another biopsy necessary to try to understand how to best treat it?
- Is it true that young male males, treated for inflammatory bowel disease, are at risk of developing hepatosplenic T-cell lymphoma and is it because of the treatment for IBD? And if so, how can that risk be reduced?
- What is the relationship between Epstein-Barr virus and PTCL?
- What are the long range effects of taking the drug vorinostat (Zolinza®) at 400 milligrams daily for about three years?
- What would be the best treatment for pediatric ALK-positive anaplastic large cell lymphoma?
- Is there any relationship between sarcoidosis and PTCL and is it possible to confuse the diagnosis?
- Can you explain the diagnosis of PTCL with a cytotoxic T-cell phenotype?
- Do you know anything about intravenous Vitamin C as an adjunct therapy on an individual basis?
- Can you please talk about the role of PUVA or light therapy in the treatment of PTCL?
- What types of T-cell lymphomas does alisertib (MLN8237) have activity with?
- With autologous transplant, is the survival rate better now than it used to be?
- How does a patient feel after the first cycle of chemotherapy and what kinds of side effects are expected?
- Is there a maximum number of pralatrexate (Folotyn®) cycles that can be given and is a PET/CT scan necessary after each cycle?
- Can peripheral T-cell lymphoma transform into any other type of T-cell lymphoma?
- What are the chances of relapse after being in remission following an autologous transplant?
- Could you please discuss why the peripheral T-cell lymphomas are most often diagnosed at an advanced stage, where they're already stage III or IV, and how does this compare to other lymphomas?
- Is fatigue common after an autologous transplant and are there any recommendations to help alleviate the fatigue?
- Is romidepsin (Istodax®) a good choice to be taking after receiving an autologous transplant and relapsing?
- Is staying in remission largely now a function of maintaining and strengthening the immune system or do you have any other suggestions to help eradicate the cancer cells or to help keep them under control?
- How can a patient find out more information about clinical trials and are there any suggestions that you can provide about that topic?
- Are mycosis fungoides and Sezary syndrome the same?
Sponsors and Supporters
This program is sponsored by The Leukemia & Lymphoma Society and supported by a grant from Celgene Corporation.